Mothaffar F Rimawi

Mothaffar F Rimawi

UNVERIFIED PROFILE

Are you Mothaffar F Rimawi?   Register this Author

Register author
Mothaffar F Rimawi

Mothaffar F Rimawi

Publications by authors named "Mothaffar F Rimawi"

Are you Mothaffar F Rimawi?   Register this Author

47Publications

1718Reads

10Profile Views

HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis.

Cancer Treat Rev 2020 Mar 17;84:101965. Epub 2020 Jan 17.

Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Department of Medical Oncology, Hospital Clínic, Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2020.101965DOI Listing
March 2020

Towards personalized treatment for early stage HER2-positive breast cancer.

Nat Rev Clin Oncol 2019 Dec 13. Epub 2019 Dec 13.

Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0299-9DOI Listing
December 2019

Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial.

J Clin Oncol 2018 04 14;36(11):1073-1079. Epub 2018 Feb 14.

Irene L. Wapnir, Stanford University School of Medicine, Stanford, CA; Karen N. Price and Shari Gelber, Frontier Science and Technology Research Foundation, Richard D. Gelber, Frontier Science and Technology Research Foundation, Dana-Farber Cancer Institute, Harvard TH Chan School of Public Health, Harvard Medical School, Meredith M. Regan, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Stewart J. Anderson, University of Pittsburgh Graduate School of Public Health; Priya Rastogi, University of Pittsburgh Cancer Institute; Norman Wolmark, Allegheny Health Network Cancer Institute, Pittsburgh, PA; André Robidoux, Centre Hospitalier de l'Université de Montréal, Montréal, Quebec; Alexander H.G. Paterson, Tom Baker Cancer Centre, Calgary, Alberta, Canada; Miguel Martín, CIBERONC, Instituto de Investigación Sanitaria Gregorio Marañon, Universidad Complutense, Madrid; José Manuel Baena-Cañada, Hospital Puerta del Mar, Cádiz, Spain; Johan W.R. Nortier, Leids Universitair Medisch Centrum, Leiden, Netherlands; Mothaffar F. Rimawi, Duncan Comprehensive Cancer Center at Baylor College of Medicine, Houston, TX; István Láng, National Institute of Oncology, Budapest, Hungary; Beat Thürlimann, Kantonsspital, St. Gallen; Stefan Aebi, Lucerne Cantonal Hospital and University of Bern, Switzerland; Eleftherios P. Mamounas, Orlando Health University of Florida Health Cancer Center, Orlando, FL; Charles E. Geyer Jr, Virginia Commonwealth University Massey Cancer Center, Richmond, VA; and Alan S. Coates, University of Sydney, Sydney, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.5719DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891132PMC
April 2018

Metastatic human epidermal growth factor receptor 2-positive breast cancer: Management, challenges, and future directions.

Curr Probl Cancer 2016 Mar - Aug;40(2-4):117-129. Epub 2016 Sep 19.

Department of Medicine, Lester and Sue Smith Breast Center, and Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine, Houston, Texas 77030.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.currproblcancer.2016.09.005DOI Listing
December 2017

De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance.

Breast 2017 Aug 4;34 Suppl 1:S19-S26. Epub 2017 Jul 4.

Lester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA; Department of Medicine, Baylor College of Medicine, Houston, TX, USA; Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX, USA; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2017.06.022DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6050048PMC
August 2017

Retrospective review of genomic testing in breast cancer: Does it improve outcome?

Breast Cancer Res Treat 2017 May 21;163(1):191-195. Epub 2017 Feb 21.

Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-017-4154-3DOI Listing
May 2017

FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer.

Proc Natl Acad Sci U S A 2016 10 6;113(43):E6600-E6609. Epub 2016 Oct 6.

Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030; Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030; Department of Medicine, Baylor College of Medicine, Houston, TX 77030;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1612835113DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5087040PMC
October 2016

Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.

J Clin Oncol 2016 Mar 1;34(9):945-52. Epub 2016 Feb 1.

Rachel A. Freedman, Rebecca S. Gelman, Christina Herold, Nicole Ryabin, Sarah Farooq, Elizabeth Lawler, Ian E. Krop, Eric P. Winer, and Nancy U. Lin, Dana-Farber Cancer Institute; Beverly Moy, Massachusetts General Hospital; Alarice Lowe and Nathalie Y.R. Agar, Brigham and Women's Hospital, Boston, MA; Jeffrey S. Wefel, Kenneth R. Hess, and Nuhad Ibrahim, The University of Texas MD Anderson Cancer Center; Polly A. Niravath and Mothaffar F. Rimawi, Baylor College of Medicine, Houston, TX; Michelle E. Melisko, University of California, San Francisco, San Francisco, CA; Roisin M. Connolly and Antonio C. Wolff, Johns Hopkins University, Baltimore, MD; Catherine H. Van Poznak, University of Michigan, Ann Arbor, MI; Shannon L. Puhalla, University of Pittsburgh Cancer Institute and Magee-Women's Hospital, Pittsburgh, PA; Kimberly L. Blackwell, Duke University Medical Center, Durham, NC; and Minetta C. Liu, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2016/01/28/JCO.2015.63
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2015.63.0343
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.63.0343DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070554PMC
March 2016

Resistance to Anti-HER2 Therapies in Breast Cancer.

Am Soc Clin Oncol Educ Book 2015 :e157-64

From the Lester and Sue Smith Breast Center and Dan L. Duncan Cancer Center at Baylor College of Medicine, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2015.35.e157DOI Listing
February 2016

Targeting HER2 for the treatment of breast cancer.

Annu Rev Med 2015 ;66:111-28

Lester and Sue Smith Breast Center and the Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas, 77030; email: , ,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1146/annurev-med-042513-015127DOI Listing
September 2015

Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003).

J Clin Oncol 2015 Aug 13;33(24):2623-31. Epub 2015 Jul 13.

Nancy U. Lin, Hao Guo, Nicole Ryabin, Julie S. Najita, William T. Barry, Ian E. Krop, Eric P. Winer, and Annick D. Van den Abbeele, Dana-Farber Cancer Institute; Andrea L. Richardson and Annick D. Van den Abbeele, Brigham and Women's Hospital, Boston, MA; Jeffrey T. Yap, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Ingrid A. Mayer and Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN; Carla I. Falkson, University of Alabama, Birmingham, AL; Timothy J. Hobday, Mayo Clinic, Rochester, MN; E. Claire Dees, University of North Carolina, Chapel Hill, NC; Rita Nanda, University of Chicago, Chicago, IL; Mothaffar F. Rimawi, Baylor College of Medicine, Houston, TX; and Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.0353DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4534525PMC
August 2015

Circulating tumor cell analysis in metastatic triple-negative breast cancers.

Clin Cancer Res 2015 Mar 18;21(5):1098-105. Epub 2014 Dec 18.

University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-1948DOI Listing
March 2015

Aromatase inhibitor adverse effects: are we sweeping them under the rug?

J Clin Oncol 2014 Nov 25;32(33):3779. Epub 2014 Aug 25.

Lester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.56.9640DOI Listing
November 2014

Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.

Breast Cancer Res Treat 2014 Apr 20;144(2):263-72. Epub 2014 Feb 20.

Lester and Sue Smith Breast Center and Dan L Duncan Cancer Center, Baylor College of Medicine, One Baylor Plaza, BCM:600, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-014-2878-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4030601PMC
April 2014

Predictors of post-mastectomy reconstruction in an underserved population.

J Plast Reconstr Aesthet Surg 2013 Jun 10;66(6):763-9. Epub 2013 Apr 10.

Division of Plastic Surgery, Michael E. Debakey Department of Surgery, Baylor College of Medicine, 6701 Fannin St. Suite 610, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bjps.2013.02.018DOI Listing
June 2013

Jejunal intussusception due to malignant phyllodes tumor of the breast.

Clin Breast Cancer 2012 Jun 28;12(3):219-21. Epub 2012 Feb 28.

Department of Internal Medicine, Baylor College of Medicine, 1709 Dryden Road, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2012.01.007DOI Listing
June 2012

Breast Cancer: Blocking both driver and escape pathways improves outcomes.

Nat Rev Clin Oncol 2012 Feb 14;9(3):133-4. Epub 2012 Feb 14.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2012.9DOI Listing
February 2012

β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib.

Breast Cancer Res 2011 Aug 31;13(4):R84. Epub 2011 Aug 31.

Lester and Sue Smith Breast Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77054, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/bcr2936DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236347PMC
August 2011

Self-blame, self-forgiveness, and spirituality in breast cancer survivors in a public sector setting.

J Cancer Educ 2010 Sep 26;25(3):343-8. Epub 2010 Feb 26.

Department of Psychiatry, Ireland Cancer Center, University Hospitals Case Medical Center, 11100 Euclid Avenue, Cleveland, OH 44106, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s13187-010-0048
Web Search
http://link.springer.com/10.1007/s13187-010-0048-3
Publisher Site
http://dx.doi.org/10.1007/s13187-010-0048-3DOI Listing
September 2010